By Matthew Dalton

PARIS--Sanofi and U.S. drugmaker Regeneron Pharmaceuticals, Inc. Monday said that their jointly developed cholesterol drug Praluent met targets in a clinical trial, reducing cholesterol in people with a hereditary high-cholesterol disorder and lowering the need for an expensive procedure to cut cholesterol levels.

Praluent had been approved by regulators last year, on condition that the companies continued studies with human subjects. The drug is intended for patients with high cholesterol who don't respond to statins, the drugs most commonly prescribed to treat the condition.

Write to Matthew Dalton at matthew.dalton@wsj.com

(END) Dow Jones Newswires

August 29, 2016 03:28 ET (07:28 GMT)